Preventive and Predictive Genetics: Towards Personalised Medicine
暂无分享,去创建一个
[1] M. Wiese,et al. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis , 2013, Expert opinion on drug metabolism & toxicology.
[2] J. Guimarães,et al. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. , 2013, JAMA neurology.
[3] M. Tamm,et al. DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1 , 2010, Respiratory research.
[4] A. Szczepankiewicz,et al. [Association of A/T polymorphism of the CHRM2 gene with bronchodilator response to ipratropium bromide in asthmatic children]. , 2008, Pneumonologia i alergologia polska.
[5] Herb Chen,et al. Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro , 2012, Neuroendocrinology.
[6] T. Mizutani. PM Frequencies of Major CYPs in Asians and Caucasians , 2003, Drug metabolism reviews.
[7] G. Aliev,et al. Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs , 2013 .
[8] R. Cacabelos. Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s Disease , 2012, Molecular Diagnosis & Therapy.
[9] D. Blacker,et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.
[10] G. Baker,et al. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? , 2007, Journal of psychiatry & neuroscience : JPN.
[11] Ammar Al-Chalabi,et al. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? , 2011, Nature Reviews Neurology.
[12] Colin N A Palmer,et al. Tailored second-line therapy in asthmatic children with the Arg(16) genotype. , 2013, Clinical science.
[13] Janel O. Johnson,et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.
[14] J. Losy,et al. CCL5, CXCL10 and CXCL11 Chemokines in Patients with Active and Stable Relapsing-Remitting Multiple Sclerosis , 2010, Neuroimmunomodulation.
[15] R. Cacabelos,et al. Genomics and Pharmacogenomics of Schizophrenia , 2011, CNS neuroscience & therapeutics.
[16] K. Misulis,et al. DEMYELINATING diseases. , 1952, Lancet.
[17] R. Cacabelos. Pharmacogenomics of Alzheimer’s Disease , 2011 .
[18] M. Tachikawa,et al. Roles of organic anion/cation transporters at the blood–brain and blood–cerebrospinal fluid barriers involving uremic toxins , 2011, Clinical and Experimental Nephrology.
[19] E. Urcelay,et al. IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.
[20] M. Nishimura,et al. Polymorphisms in the muscarinic receptor 1 gene confer susceptibility to asthma in Japanese subjects. , 2006, American journal of respiratory and critical care medicine.
[21] K. Barnes. Ancestry, ancestry-informative markers, asthma, and the quest for personalized medicine. , 2010, The Journal of allergy and clinical immunology.
[22] Y. Okamoto,et al. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. , 2011, American journal of cancer research.
[23] R. Cacabelos. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders , 2009, The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes.
[24] R. Kim,et al. Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.
[25] X. Montalban,et al. Role of tumour necrosis factor (TNF)‐α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor‐associated periodic syndrome and multiple sclerosis , 2011, Clinical and experimental immunology.
[26] V. Haufroid. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. , 2011, Current drug targets.
[27] Yoo-Hun Suh,et al. Amyloid Precursor Protein, Presenilins, and α-Synuclein: Molecular Pathogenesis and Pharmacological Applications in Alzheimer's Disease , 2002, Pharmacological Reviews.
[28] A. Townsend,et al. Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux , 2006, Molecular Pharmacology.
[29] D. Shriner. Overview of Admixture Mapping , 2017, Current protocols in human genetics.
[30] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[31] C. Winkler,et al. Admixture mapping comes of age. , 2010, Annual review of genomics and human genetics.
[32] R. Cacabelos. The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders , 2012 .
[33] Keith F. Tipton,et al. The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.
[34] D. Meyers,et al. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. , 2014, The Journal of allergy and clinical immunology.
[35] Z. Kovarik,et al. Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers. , 2011, Biochimie.
[36] O. Ross. A Prognostic View on the Application of Individualized Genomics in Parkinson’s Disease , 2013, Current Genetic Medicine Reports.
[37] J. Robert,et al. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38 , 2004, Clinical pharmacology and therapeutics.
[38] A. Crowe,et al. Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. , 2012, Toxicology and applied pharmacology.
[39] J. Donfack,et al. Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. , 2003, The Journal of allergy and clinical immunology.
[40] P. Gergen,et al. Reported asthma among Puerto Rican, Mexican-American, and Cuban children, 1982 through 1984. , 1993, American journal of public health.
[41] R. Chakraborty,et al. V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. , 2002, Journal of immunology.
[42] A. Goris,et al. Send Orders of Reprints at Reprints@benthamscience.org Progress in Multiple Sclerosis Genetics , 2022 .
[43] Pamela A McCombe,et al. Effects of gender in amyotrophic lateral sclerosis. , 2010, Gender medicine.
[44] C. Polman,et al. Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.
[45] Lee, Jk,et al. Lebrikizumab treatment in adults with asthma. , 2011 .
[46] Anil K. Malhotra,et al. Genomics and the future of pharmacotherapy in psychiatry , 2007, International review of psychiatry.
[47] Matthew C. Kiernan,et al. Clinical diagnosis and management of amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.
[48] S. Ying,et al. Intron-mediated RNA interference and microRNA biogenesis. , 2009, Methods in molecular biology.
[49] N. Hanania,et al. Periostin, a novel biomarker of TH2-driven asthma , 2014, Current opinion in pulmonary medicine.
[50] R. Bhatnagar,et al. RNA Interference: Biology, Mechanism, and Applications , 2003, Microbiology and Molecular Biology Reviews.
[51] K. Rhodes,et al. Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway , 2012, Journal of Pharmacology and Experimental Therapeutics.
[52] R. Cacabelos. Pharmacogenomics and therapeutic strategies for dementia , 2009, Expert review of molecular diagnostics.
[53] I. Pavord,et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.
[54] D. Selkoe,et al. Deciphering the genetic basis of Alzheimer's disease. , 2002, Annual review of genomics and human genetics.
[55] S. Wenzel,et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.
[56] W. Waldhäusl,et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. , 2005, Arthritis and rheumatism.
[57] K. Biglan,et al. Therapeutics in Huntington’s Disease , 2012, Current Treatment Options in Neurology.
[58] S. Szabo,et al. Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet , 2002, Science.
[59] W. Poewe,et al. Management of Motor and Non-Motor Symptoms in Parkinson’s Disease , 2013, CNS Drugs.
[60] Ryan M Spengler,et al. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[61] K. Német,et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance , 2008, Annals of the rheumatic diseases.
[62] R. Cacabelos. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. , 2007, Methods and findings in experimental and clinical pharmacology.
[63] Florence Demenais,et al. A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.
[64] N. Farahi,et al. Asthma: beyond corticosteroid treatment , 2013, Archives of medical science : AMS.
[65] R. Cacabelos. Pharmacogenomics and therapeutic prospects in dementia , 2008, European Archives of Psychiatry and Clinical Neuroscience.
[66] T. Ishikawa,et al. Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). , 2004, Biological & pharmaceutical bulletin.
[67] P. Barnes,et al. New drugs for asthma , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[68] A. Wimo,et al. The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.
[69] Magnus Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[70] I. Tellado,et al. Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants , 2010, Pharmaceuticals.
[71] Yoshiro Saito,et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. , 2004, Drug metabolism and pharmacokinetics.
[72] J. Sattabongkot,et al. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. , 2006, Toxicology and applied pharmacology.
[73] R. Cacabelos. Pharmacogenomics of Central Nervous System (CNS) Drugs , 2012 .
[74] R. Cacabelos,et al. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. , 2000, Methods and findings in experimental and clinical pharmacology.
[75] C. Brightling,et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.
[76] J. Stevens,et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. , 1997, The Journal of pharmacology and experimental therapeutics.
[77] H. Pehamberger,et al. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. , 2010, The Journal of investigative dermatology.
[78] A. Puschmann. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. , 2013, Parkinsonism & related disorders.
[79] Hung Li,et al. Carrier Screening for Spinal Muscular Atrophy (SMA) in 107,611 Pregnant Women during the Period 2005–2009: A Prospective Population-Based Cohort Study , 2011, PloS one.
[80] Andrew D. Johnson,et al. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. , 2005, Pharmacology & therapeutics.
[81] F. Patti,et al. The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment , 2013, Expert opinion on drug metabolism & toxicology.
[82] P. Jarman,et al. Genetics of movement disorders and ataxia , 2002, Journal of neurology, neurosurgery, and psychiatry.
[83] A. Need,et al. Priorities and standards in pharmacogenetic research , 2005, Nature Genetics.
[84] P. Couraud,et al. ABC AND SLC TRANSPORTER EXPRESSION AND POT SUBSTRATE CHRACTERIZATION ACROSS THE HUMAN CMEC/ D3 BLOOD-BRAIN BARRIER CELL LINE , 2010 .
[85] M. Armstrong,et al. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease , 2012, Neurology.
[86] C. Vedeler,et al. Fc receptors for immunoglobulin G—a role in the pathogenesis of Guillain–Barré syndrome and multiple sclerosis , 2001, Journal of Neuroimmunology.
[87] K. Ohta,et al. Mutation screening of the muscarinic m2 and m3 receptor genes in asthmatics, outgrow subjects, and normal controls. , 2002, Annales de genetique.
[88] M. Kubo,et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. , 2014, The Journal of allergy and clinical immunology.
[89] Wei Duan,et al. Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.
[90] D. Postma,et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction , 2009, Nature Genetics.
[91] M. Bromberg,et al. Amyotrophic Lateral Sclerosis: Drug Therapy from the Bench to the Bedside , 2012, Seminars in Neurology.
[92] R. Weinshilboum,et al. Pharmacogenetics and pharmacogenomics: development, science, and translation. , 2006, Annual review of genomics and human genetics.
[93] E. Cook,et al. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. , 2004, Pharmacogenetics.
[94] Paweł P Liberski,et al. Gerstmann-Sträussler-Scheinker disease. I. Human diseases. , 2004, Folia neuropathologica.
[95] M. Takeda,et al. Molecular genetics of Alzheimer's disease and aging. , 2005, Methods and findings in experimental and clinical pharmacology.
[96] M. Nishimura,et al. Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. , 2008, Drug metabolism and pharmacokinetics.
[97] S. Wenzel,et al. Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.
[98] F. Van Bambeke,et al. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. , 2011, Current drug targets.
[99] S. Cavallaro,et al. Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways , 2012, Current genomics.
[100] P. Whittaker,et al. RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.
[101] Vincenzo Bonifati,et al. The genetics of Parkinson's disease: Progress and therapeutic implications , 2013, Movement disorders : official journal of the Movement Disorder Society.
[102] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[103] J. Márki-Zay,et al. MDR-ABC transporters: biomarkers in rheumatoid arthritis. , 2013, Clinical and experimental rheumatology.
[104] P. Casarosa,et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. , 2013, Journal of medicinal chemistry.
[105] Christos Proukakis,et al. A novel α-synuclein missense mutation in Parkinson disease , 2013, Neurology.
[106] R. Cacabelos. Pharmacogenomics and therapeutic prospects in Alzheimer’s disease , 2005, Expert opinion on pharmacotherapy.
[107] K. Wolff,et al. Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF-κB/p65 in Human Endothelial Cells1 , 2002, The Journal of Immunology.
[108] J. Leszek,et al. Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics , 2012, International journal of Alzheimer's disease.
[109] Carmen Fraile,et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. , 2007, Current Alzheimer research.